Thursday, October 8, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 16, 2026

Park Aerospace (PKE) Q3 2026 Earnings Transcript

View original at nasdaq.com
Park Aerospace (PKE) Q3 2026 Earnings Transcript Image source: The Motley Fool. DATE Tuesday, January 13, 2026 at five p.m. ET CALL PARTICIPANTS Executive Chairman — Brian ShorePresident and Chief Operating Officer — Mark A…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • LEAP 1A engine has 64.5% firm order market share versus Pratt & Whitney GTF based on thousands of total orders/backlog

    80% confidence
  • Multiple confidential missile programs represent very significant revenue opportunities over long periods but too confidential or sensitive to identify at this time

    80% confidence
  • Park committed €50K (50/50 split) for joint economic study with Arian for potential major C2B fabric manufacturing facility in U.S., expense expected in Q4

    80% confidence
  • Park is sole source qualified for specialty ablative materials on PAC-3 missile system program

    80% confidence
  • Q3 missed shipments of $740K due to international freight, supply chain, and spec/engineering issues

    80% confidence
  • Q4 GE Aerospace program sales forecast of $7.25M-$8.25M

    80% confidence
  • Post-expansion capacity estimate of ~$260M annually when 'pushing it' while maintaining Park approach

    80% confidence
  • Park has paid dividends for 41 consecutive years totaling $29.72 per share since 2005

    80% confidence
  • Maximum theoretical post-expansion capacity of ~$315M-$320M annually under mill operation (6 days/24 hours, not desired)

    80% confidence
  • New facility operational (producing/selling qualified product) targeted for second half of calendar 2028

    80% confidence
  • Lockheed Martin PAC-3 production capacity expanded from 375 units (2 years ago) to 600 (current) with target of 2,000 units annually, 60% increase in last 2 years alone

    80% confidence
  • Airbus A320neo family has 4,275 delivered through November 2025, backlog of 7,900+ aircraft, total 12,000+ aircraft

    80% confidence
  • Park recently asked to increase expected output by significant orders of magnitude for missile programs

    80% confidence
  • Ukraine PAC-3 systems seriously depleted

    80% confidence
  • Capital spend timing: ~60% in FY2027, ~30% in FY2028, ~10% in FY2029

    80% confidence
  • Israel PAC-3 systems seriously depleted

    80% confidence
  • New facility completion targeted for second half of calendar 2027

    80% confidence
  • Boeing 777X has 600+ orders with FAA certification/EIS/first delivery now expected in 2027, in Phase 3 of certification testing

    80% confidence
  • Pentagon pushing for 2x-4x missile production increases on breakneck schedule per Wall Street Journal

    80% confidence
  • Q4 FY2026 revenue guidance of $23.5M-$24.5M including ~$7.2M C2B fabric sales (low-margin)

    80% confidence
  • We think Trump administration defense policy is great, wonderful. Park already building factory without incentives/encouragement.

    80% confidence
  • Unprecedented demand for missile systems with urgent need to replenish seriously depleted stockpiles from wars in Europe and Mideast

    80% confidence
  • CFM significantly ramped up production deliveries

    80% confidence
  • Pratt & Whitney engines continue serious reliability issues

    80% confidence
  • Post-expansion capacity estimate of ~$220M annually maintaining 'Park being Park' flexible approach

    80% confidence
  • Q4 FY2026 EBITDA guidance of $4.75M-$5.25M

    80% confidence
  • Boeing CEO cited increased FAA scrutiny post-737 MAX issues as factor in 777X delays

    80% confidence
  • Example of capital advantage: immediate commitment to $20M redundant factory for GE Aerospace programs secured LTA through 2029 for hundreds of millions in business; same plant would cost ~2x today due to inflation

    80% confidence
  • COMAC C909 has 75+ delivered, operating in 10-12 Asian countries, carried 30M+ passengers, 385 open orders, at production rate

    80% confidence
  • COMAC C919 expected to fall short of 2025 delivery target due to supply chain and international trade issues

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com